Used in targeted cancer therapies, particularly for solid tumors overexpressing EphA2, such as lung, prostate, and ovarian cancers. Binds specifically to EphA2 receptor, blocking tumor cell proliferation, migration, and survival signaling. Employed in antibody-drug conjugates (ADCs) to deliver cytotoxic agents directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. Also utilized in diagnostic imaging to detect EphA2-positive tumors. Investigated for its role in inhibiting angiogenesis and tumor metastasis in preclinical models.